Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in
extensive-stage non-small cell lung cancer: the Southwest Oncology Group
experience. Journal of Clinical Oncology 1991;9:1618-26.
Ando M, Ando Y, Sugiura S, et al. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Japanese Journal of Cancer Research 1999;90:249-253.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J.
Cisplatin-based adjuvant chemotherapy in patients with chompletely resected non-small-cell lung cancer. New English Journal of Medicine 2004;350:351-360
Ferguson MK, Wang J, Hoffman PC, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. The Annals of Thoracic Surgery 2000;69(1):245-249
Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer 1996;77(9):1947-1965
Harpole Jr DH, Herndon II JE, Young Jr WG, et al. Stage I non-small cell lung cancer; a multivarite alalysis of treatment methods and patterns of recurrence. Cancer 1999;76:787-796
Ihde DC. Chemotherapy of lung cancer. New English Journal of Medicine 1992;327:1434-1441
Jang TW, Kim YC, Kwon YS, et al. Female lung cancer: Re-analysis of
national survey of lung cancer in Korea, 2005. Journal of Lung Cancer 2010;9(2):57-63
Kabat GG, Wynder EL. Lung cander in nonsmoker. Cancer 1984;53:1214-1221 Kamangar Farin, Dores GM and Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world.
Journal of Clinical Oncology. 2006;24(14):2137-2150
Kim YC, Kwon YS, Oh IJ, et al. National survey of lung cancer in Korea, 2005.
Journal of Lung Cancer 2007;6(2):67-7
Lam WK, So Sy, Yu DYC, et al. Clinical features of bronchogenic carcinoma in Hong Kong. Cancer 1983;52:369-376
Nicolas Girard, Pascale Jacoulet, Marie Gainet, et al. Thire-line chemotherapy in advanced non-small cell lung cancer: identifying the candiated for routine practice. Journal of Thoracic Oncology 200;4(12):1544-1549.
Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal 1995;311:899-909
Park SJ, Choi IK, Seo HY, et al. Treatment results including more than third-line chemotherapy for patients wit advanced non-small cell lung cancer.
Oncology Letters 2010;1:51-55.
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LaCE Collaborative Group. Journal of Clinical Oncology 2008;26:3552-3559
Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute 2000;92(13):1074-80
Rebecca Siegel, Deepa Naishadham, Ahmedin Jemal. Cancer Statistics, 2012. CA Cancer Journal of Clinical 2012;62:10-29
Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, 2008
Rivera MP, Stover DE. Gender and lung cancer. Clin Chest Med 2004;25:391-400 Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter,
randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27(3):145-57
Roszkowski K, Pluzanska A, Krzakowki M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastic or non-rectable localized non-small cell lung cancer(NSCLC). Lung Cancer 2000;27(3):145-57 Shinsuke Saisho, Koichiro Yasuda, Ai Maeda, et al. Post-recurrence survival of
patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interactive CardioVascular and Thoracic Surgery 2013;16:166-172
Song IH, Yeom SW, Heo SH, et al. Prognostic factors for post-recurrence survival in patients with completely resected stage I non-small-cell lung cancer.
European Journal of Cardio-Thoracic Surgery 2013;Epub:-6
Souquet PJ, Chauvin F, Boissel JP. Polychemotherapy in advanced non small cell lung cancer: a meta-alalysis. Lancet 1993;342;19-21
Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analysis including recursive partitioning and amalgamation. Lung cacner
1996;15:67-77
Teeter SM, Holmes FF, McFariane MJ. Lung carcinoma in the elderly population.
Cancer 1987;60:1331-1336
Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care(BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24(1):17-24
Williams DE, Pairolero PC, Davix CS, et al. Survival of patients surgically treated for stage I lung cancer. The Journal of Thoracic and Cardiovascular Surgery 1981;82(1):70-76
Wynder El, Grahan EA. Tabaco smoking as a possible etiologic factor in bronchogenic carcinoma. A study of six of hundred and eighty-four proved cases. The Journal of the American Medical Association
1950;143:329-336
Zietemann V., Duell T. Prevalence and effectiveness of first-, second-, and
third-line systemictherapy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer 2011;73:70-77.
부록 1. CRF(Case Report Form)
￡PET-CT Bone scan Abdominal CT
□ □ □
치료 II.
수술 여부 □ 예 □ 아니오
수술 후 재발 여부 □ 예 □ 아니오
최초 치료 약물 □ Gemcitabine □ Docetaxel □ Paclitaxel □ Alimta Irresa Cisplatin Carboplatin
□ □ □
최종 추적 조사 최종 상태 : □ 생존 □ 사망 □ Not known 최종 추적일 : 년 월 일
만성폐쇄성 폐질환
* COPD: Chronic Obstructive Pulmonary Disease
결핵 특발성 폐섬유화
** Tbc: Tuberculosis , *** IPF: Idiopathic Pulmonary Fibrosis 증, **** Pneumoconiosis 진폐증
￡Kim YC, Kwon YS, Oh IJ, et al. National survey of lung cancer in Korea, 2005.
Journal of Lung Cancer 2007;6(2):67-7
Abstract
Outcome and prognostic factors of palliative chemotherapy for non-small cell lung cancer patients at single institution: 2002-2011
Jeong Geum-Sook Graduate School of Public Health Ajou University
This study is related to general and clinicopathologic characteristics of non-small cell lung cancer patients who received palliative chemotherapy, overall survival, and factors that affect the survival rates. The study subjects were 402 non-small cell lung cancer patients who received palliative chemotherapy during 10 years from January 2002 to December 2011 at a university hospital. The data were processed using an SPSS 20.0 program and survival rates were analyzed using log rank tests and Cox's proportional hazards model. Major results are as follows.
1. The total number of study patients was 402, their median age was 59 years, and their ages were distributed between 30 years and 80 years. As for the patients' distribution among age groups, 431(84.8%) patients were younger than 70 years and 61(15.2) patients were 70 years old or older. With regard to gender distribution, 259(64.4%) patients were males and 143(35.6%) patients were females with a male/female ratio of 1.81:1 meaning that the number of males was larger by 1.81 times. As for smoking histories, the number of the smoking group was 236(58.7%) and number of the non-smoking group was 145(36.1%) meaning that
the number of the smoking group was larger by 1.63 times.
2. As for the study patients' clinicopathologic characteristics, 300(74.6%) patients were in the ECOG performance status (PS) 0,1 groups, 31(7.7%) patients were in the ECOG PS 2,3 groups and 71(17.7%) patients had missing values indicating that palliative chemotherapy was mainly performed in groups with good ECOG PS. As for disease stages, 15(3.7%) patients were in stage IIIA, 48(11.9%) patients were in stage IIIB, 256(63.7%)patients were in stage IV, and 83(20.6%)patients had missing values. As for histologic types, 74(18.4%) patients were squamous cell carcinoma and 328(81.6%) patients were non-squamous cell carcinoma.
3. As for palliative chemotherapy-related characteristics, 296(73.6%) patients received combination chemotherapy as first line therapy and 106(26.4%) patients received single agent chemotherapy as first line therapy. The results of lines of chemotherapy indicated that 163(40.6%) patients received first line therapy only, 124(30.8%) patients received second line therapy, and 115(28.6%) patients received third or later line of therapy.
4. In survival analysis, the median survival period of all patients was 11 months, one year overall survival was 48.3%, two year overall survival was 22.1%, three year overall survival was 12%, and five year overall survival was 3.6%. Univariate analysis showed that variables with statistical significance were sex(p<0.0001), age(p=0.013), smoking history(p<0.0001), ECOG PS(p=0.004), histologic types(p=0.009), lines of chemotherapy(p<0.0001), and disease status(primary advanced or recurrent)(p=0.010).
5. Multivariate analysis showed that sex, the number of times of drug changes, and disease status had statistically significant effects on mortality risks. The analysis with sex showed that the mortality risk of males was higher by 1.4 times
than females(p=0.006) and the analysis with the number of times of changes in chemotherapy showed that the mortality risk of second line therapy was 1.8 times higher than that of third or later line of therapy and the mortality risk of first line therapy was 2.3 times higher than that of third of later line of therapy(p<0.0001). The analysis of disease status demonstrated that the mortality risk of the primary advanced lung cancer group was 1.6 times higher than that of the postoperative recurrent lung cancer group(p=0.035)
Because this study was conducted with only patients in a university hospital in Suwon, the results cannot represent the characteristics of lung cancer in the entire Korea. This study has a limitation that the quality of information obtained in this study may be a little lower compared to prospective studies because this study is a retrospective study and information bias may be involved.
In conclusion, the significance prognostic factors of non-small cell lung cancer patients who received palliative chemotherapy were sex, the number of times of regimen changes, and primary advanced disease status. Mortality risks were shown to be higher among males compared to females, higher in patients who received first or second line of therapy compared with those who received third or later line of therapy, and higher in the primary advanced lung cancer group compared to the postoperative recurrent lung cancer group. In terms of public health, it is considered that studies are necessary to find and treat lung cancer patients earlier along with multilateral nonsmoking policies because the prognosis of lung cancer is very poor if the disease is diagnosed at advanced status and there is no special screening test. In terms of clinical aspects, it is considered that studies of female lung cancer patients with no smoking history and studies for outcome of patients who received first line, second line, third or later line of chemotherapy should be
continuously conducted.
Keywords; palliative chemotherapy, non-small cell lung cancer, survival, prognostic factors